Research prototype, not medical advice.

In a phase IIa trial, mTORC1 inhibitors improved vaccine response and reduced infections in older people.

Confidence
Established
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Chronic inflammationmTOR (mTORC1)Deregulated nutrient sensing

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports TORC1 inhibition enhances immune function and reduces infections in the elderly
Mannick et al. · Science Translational Medicine 2018
— Verified

Related claims